Proteostasis Therapeutics, Inc. (PTI) Stock Rating Reaffirmed by Leerink Swann

Proteostasis Therapeutics, Inc. (NASDAQ:PTI)‘s stock had its “outperform” rating reissued by research analysts at Leerink Swann in a research report issued on Wednesday. They currently have a $9.00 price target on the stock, down from their prior price target of $17.00. Leerink Swann’s price target suggests a potential upside of 341.18% from the stock’s previous close.

A number of other brokerages have also commented on PTI. Zacks Investment Research raised Proteostasis Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Proteostasis Therapeutics in a research report on Friday, June 30th.

Proteostasis Therapeutics (NASDAQ:PTI) opened at 2.04 on Wednesday. Proteostasis Therapeutics has a 52-week low of $1.97 and a 52-week high of $18.99. The stock’s 50 day moving average price is $3.45 and its 200 day moving average price is $7.28. The firm’s market capitalization is $51.21 million.

ILLEGAL ACTIVITY WARNING: “Proteostasis Therapeutics, Inc. (PTI) Stock Rating Reaffirmed by Leerink Swann” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.com-unik.info/2017/08/18/proteostasis-therapeutics-inc-pti-stock-rating-reaffirmed-by-leerink-swann.html.

A number of institutional investors have recently added to or reduced their stakes in PTI. Susquehanna International Group LLP bought a new position in Proteostasis Therapeutics during the second quarter worth about $254,000. Goldman Sachs Group Inc. increased its position in Proteostasis Therapeutics by 364.3% in the second quarter. Goldman Sachs Group Inc. now owns 51,911 shares of the company’s stock worth $243,000 after buying an additional 40,731 shares during the period. Bain Capital Public Equity Management LLC bought a new position in Proteostasis Therapeutics during the second quarter worth about $1,233,000. Dimensional Fund Advisors LP bought a new position in Proteostasis Therapeutics during the second quarter worth about $296,000. Finally, FMR LLC increased its position in Proteostasis Therapeutics by 2.3% in the second quarter. FMR LLC now owns 2,944,915 shares of the company’s stock worth $13,782,000 after buying an additional 66,111 shares during the period. Institutional investors and hedge funds own 75.40% of the company’s stock.

Proteostasis Therapeutics Company Profile

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

What are top analysts saying about Proteostasis Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Proteostasis Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit